(Q37509280)

20 August 2017

1 reference

title

Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease (English)

1 reference

20 August 2017

2

1 reference

20 August 2017

Catherine Fiévet

1

1 reference

20 August 2017

1 July 2009

1 reference

Current Atherosclerosis Reports

20 August 2017

1 reference

20 August 2017

11

1 reference

20 August 2017

4

1 reference

20 August 2017

281-288

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-009-0043-5

20 August 2017

0 references

cites work

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0043-5

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0043-5

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

21 January 2018

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes

1 reference

12 December 2020

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

1 reference

12 December 2020

Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial

1 reference

12 December 2020

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

1 reference

12 December 2020

Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease

1 reference

12 December 2020

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

1 reference

12 December 2020

Rosiglitazone RECORD study: glucose control outcomes at 18 months

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia

1 reference

12 December 2020

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

12 December 2020

Rosiglitazone and delayed onset of proliferative diabetic retinopathy

1 reference

12 December 2020

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

1 reference

12 December 2020

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

12 December 2020

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

12 December 2020

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.

1 reference

12 December 2020

High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study

1 reference

12 December 2020

Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.

1 reference

12 December 2020

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

12 December 2020

Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus

1 reference

12 December 2020

Effects of intensive glucose lowering in type 2 diabetes

1 reference

12 December 2020

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

1 reference

12 December 2020

Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes.

1 reference

12 December 2020

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

1 reference

12 December 2020

The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation

1 reference

12 December 2020

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

12 December 2020

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

1 reference

12 December 2020

Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists

1 reference

12 December 2020

Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production

1 reference

12 December 2020

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

1 reference

12 December 2020

Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation

1 reference

12 December 2020

A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes

1 reference

12 December 2020

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

12 December 2020

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

12 December 2020

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus

1 reference

12 December 2020

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

1 reference

12 December 2020

PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a

1 reference

12 December 2020

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

12 December 2020

Rosiglitazone decreases albuminuria in type 2 diabetic patients.

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

12 December 2020

Thiazolidinedione-induced edema

1 reference

12 December 2020

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

1 reference

12 December 2020

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

12 December 2020

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

1 reference

12 December 2020

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice

1 reference

12 December 2020

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

1 reference

12 December 2020

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

1 reference

12 December 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

Fibrates and microvascular complications in diabetes--insight from the FIELD study

1 reference

12 December 2020

10.1007/S11883-009-0043-5

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19500491